Sarepta Therapeutics Inc. (srpt 1.25 09/15/27)
13F holders, Q1 2025 (March 31)11holders +2
4new positions
3sold out
$0.91avg. 13F price*
At the end of Q1 2025, 11 institutions reported holding Sarepta Therapeutics Inc. (srpt 1.25 09/15/27) in their 13F filings, up 2 from Q4 2024. 4 opened new positions and 3 sold out. The largest holders were New York State Common Retirement Fund ($7.4M), BNP PARIBAS ASSET MANAGEMENT Holding S.A. ($4.1M) and Ofi Invest Asset Management ($3.5M).
- Company
- Sarepta Therapeutics Inc. (srpt 1.25 09/15/27)
- CUSIP
- 803607AD2
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $151K |
| Exits | 3 | $22.6M |
All 13F filers, Q4 2024 → Q1 2025: 1,961,519 shares bought and 2,685,353 shares sold, net −723,834 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| New York State Common Retirement Fund | 0.01% | Add +29.4% | 7,923,000 | $7.4M |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.01% | Reduce 0.0% | 4,399,999 | $4.1M |
| Ofi Invest Asset Management | 0.09% | No change | 4,000,000 | $3.5M |
| Bank of New York Mellon Corp | 0.00% | No change | 500,000 | $466K |
| &partners | 0.00% | New | 88,000 | $83K |
| B. Riley Wealth Advisors, Inc. | 0.00% | New | 37,000 | $34K |
| Cetera Investment Advisers | 0.00% | New | 36,000 | $33K |
| Choreo, LLC | 0.00% | Reduce -26.5% | 25,000 | $23K |
| Lanark Financial, Inc. | 0.00% | — | 8,000 | $7K |
| Rothschild Investment LLC | 0.00% | No change | 1,000 | $929 |
| Laffer Tengler Investments, Inc. | 0.00% | New | 519 | $485 |
"% of holder's portfolio" is SAREPTA THERAPEUTICS INC (SRPT 1.25 09/15/27)'s weight in each manager's 13F, not the share of Sarepta Therapeutics Inc. (srpt 1.25 09/15/27) the manager owns.